You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 7, July 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Interleukin-1 Receptor Antagonist in Head and Neck Squamous Cell Carcinoma

S. Elizabeth von Biberstein, MD; Jeffrey D. Spiro, MD; Richard Lindquist, MD; Donald L. Kreutzer, PhD

Arch Otolaryngol Head Neck Surg. 1996;122(7):751-759.


Abstract

Background
We hypothesized that in head and neck squamous cell carcinoma, the overexpression of protumorigenic interleukin-1 (IL-1) activity within the tumor tissue is a result of decreased expression of the specific antagonist or inhibitor (ie, IL-1 receptor antagonist) by the tumor cells. Ultimately, this local overexpression of IL-1 activity increases tumor growth and metastasis.

Design
To test our hypotheses, immunologic analysis for IL-1{alpha}, IL-1β, and IL-1 receptor antagonist was performed on histologic sections and tumor homogenates of human head and neck squamous cell carcinomas.

Setting
University teaching hospital.

Patients or Other Participants
Normal and tumor specimens were obtained from patients undergoing surgical resections of the head and neck for benign and malignant disease.

Results
Immunohistochemical analysis demonstrated the presence of IL-1{alpha}, IL-1β, and IL-1 receptor antagonist within tumor cells and inflammatory cells in the tumor stroma in 19 of 19 tumor specimens. Quantitatively, IL-1{alpha} was present in 19 of 19 tumor specimens (1.97±0.46 ng/mg of total protein [mean±SD]) and 5 of 9 normal specimens (0.23±0.12 ng/mg of total protein). All specimens contained IL-1β in detectable quantities (1.60±0.29 ng/mg of total protein in tumor specimens and 0.189±0.04 ng/mg of total protein in normal specimens). All specimens contained IL-1 receptor antagonist (368.87±57.63 ng/mg of total protein in tumor specimens and 585.10± 166.03 ng/mg of total protein in normal specimens). The mean total IL-1/IL-1 receptor antagonist ratio was 13.26±2.31 in patients with cancer compared with 0.997±0.26 in normal patients.

Conclusions
The increased IL-1 index in the cancer state compared with the normal state reflects an imbalance of IL-1 and IL-1 receptor antagonist, which may contribute to unrestricted growth and metastasis of head and neck squamous cell carcinoma.

Arch Otolaryngol Head Neck Surg. 1996;122:751-759



Author Affiliations

From the Division of Otolaryngology and Surgical Research Center, Departments of Surgery (Drs von Biberstein, Spiro, and Kreutzer) and Pathology (Drs Lindquist and Kreutzer), University of Connecticut Health Center, Farmington.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.